Outcome Data
UPN . | SOS prophylaxis (DF mg/kg) . | SOS, Y/N . | SOS severity (moderate/severe) . | SOS treatment (DF dose in mg/kg/d) . | Cure of SOS, Y/N . | Time at last FU, mo post-HSCT . | Survival . | Karnofsky/Lansky score at last FU, % . | CD15+ DC at last FU, % . | CD3+ DC at last FU, % . | aGVHD (Glucksberg) . | cGVHD (NIH) . | Infection post-HSCT . | Other transplant-related complications post HSCT . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Hep | N | 52 | Alive | 100 | 100 | 88 | 0 | 0 | BK | Hemorrhagic cystitis | |||
2 | Hep | N | 64 | Alive | 100 | 100 | 100 | 2 | 0 | EBV | Femur head necrosis after 2 mo of steroids due to transient acute GHVD II of the liver | |||
3 | NAC | N | 16 | Alive | 100 | 100 | 100 | 2 | 0 | EBV, rhinovirus, BK | Mucositis (grade 3) | |||
4 | None | N | 8 | Alive | 40 | 100 | 100 | 2 | 0 | Fungal chest infection, ADV viremia, EBV viremia | Pancreatitis | |||
5 | Hep/NAC | N | 36 | Alive | 100 | 100 | 100 | 1 | 0 | Bacterial CVL infection | None | |||
6 | DF 25 | N | 31 | Alive | 100 | 90 | 85 | 0 | 0 | Rhinovirus, BCG | Mucositis (grade 2), PH (d+30), gut/renal salt protein losses, renal calcification (successful surgical removal) | |||
7 | DF 25 | Y | M | DF/steroids | Y | 24 | Alive | 100 | 98 | 88 | 0 | 0 | EBV, BCG | Hematemesis, rectal bleeding, diarrhea, early reactivation of HLH, renal impairment, arterial hypertension |
8 | Hep | Y | M | DF 40 | Y | 61 | Alive | 100 | 98 | 98 | 0 | 0 | N | Mucositis, GI problems, Hashimoto’s thyroiditis |
9 | NAC | Y | M | DF 40 paracentesis | Y | 15 | Alive | 100 | 9 | 42 | 0 | 0 | N | None |
10 | NAC | N | 51 | Alive | 100 | 100 | 100 | 0 | 0 | N | Mucositis (grade 1), CVL-associated atrial thrombus cured by surgical removal | |||
11 | Hep | Y | M | DF/steroids | Y | 88 | Alive | 100 | 90 | 89 | 0 | 0 | N | Mucositis (grade 2) |
12 | Hep | N | 111 | Alive | 100 | 94 | 92 | 1 | 0 | Urinary infection | Fever, mucositis (grade 2) | |||
13 | None | N | 45 | Alive | 100 | 100 | 100 | 1 | 0 | N | None | |||
14 | NAC | N | 63 | Alive | 40 | 100 | 98 | 0 | 0 | N | None | |||
15 | NAC | Y | S | DF/steroids, paracentesis, ventilation | Y | 43 | Alive | 100 | 95 | 96 | 0 | 0 | N | Mucositis (grade 2), ventilated, atelectasis left lung, urinary infection |
16 | NAC | Y | M | DF/steroids | Y | 31 | Alive | 100 | 100 | 99 | 1 | 0 | N | Recurrent CVL complications |
17 | NAC | N | 37 | Alive | 90 | 99,5 | 99,5 | 1 | 1 (oral/scalp) | Vulvitis with Pseudomonas | Mucositis (grade 2), engraftment syndrome, eosinophilic folliculitis of the scalp with partial effluvium, stomatitis, DD cGHVD | |||
18 | NAC | Y | M | DF/steroids/paracentesis | Y | 36 | Alive | 100 | 73 | 30 | 0 | 0 | N | Mucositis (grade 2) |
19 | NAC, DF 25 | N | 31 | Alive | 100 | 96 | 87 | 0 | 0 | N | None | |||
20 | NAC, DF 25 | N | 18 | Alive | 100 | 58 | 79 | 0 | 0 | Metapneumovirus, HHV-6 | None | |||
21 | Hep | N | 14 | Alive | 100 | 100 | 98,5 | 0 | 0 | Bacterial CVL infection | Mucositis grade 3 | |||
22 | None | Y | M | DF | Y | 22 | Alive | 100 | 100 | 81 | 0 | 0 | N | EBV viremia, rituximab |
23 | Hep/DF 25 | N | 8 | Alive | 100 | 67 | 74 | 0 | 0 | N | Mucositis (grade 3), seizure of unknown cause | |||
24 | NAC | N | 78 | Alive | 100 | 100 | 100 | 2 | 0 | N | Mucositis (grade 1), arterial hypertension | |||
25 | NAC | N | 49 | Alive | 100 | 97 | 97 | 2 | 0 | N | Engraftment syndrome, arthritis of 2 joints (intra-articular steroid injections) |
UPN . | SOS prophylaxis (DF mg/kg) . | SOS, Y/N . | SOS severity (moderate/severe) . | SOS treatment (DF dose in mg/kg/d) . | Cure of SOS, Y/N . | Time at last FU, mo post-HSCT . | Survival . | Karnofsky/Lansky score at last FU, % . | CD15+ DC at last FU, % . | CD3+ DC at last FU, % . | aGVHD (Glucksberg) . | cGVHD (NIH) . | Infection post-HSCT . | Other transplant-related complications post HSCT . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Hep | N | 52 | Alive | 100 | 100 | 88 | 0 | 0 | BK | Hemorrhagic cystitis | |||
2 | Hep | N | 64 | Alive | 100 | 100 | 100 | 2 | 0 | EBV | Femur head necrosis after 2 mo of steroids due to transient acute GHVD II of the liver | |||
3 | NAC | N | 16 | Alive | 100 | 100 | 100 | 2 | 0 | EBV, rhinovirus, BK | Mucositis (grade 3) | |||
4 | None | N | 8 | Alive | 40 | 100 | 100 | 2 | 0 | Fungal chest infection, ADV viremia, EBV viremia | Pancreatitis | |||
5 | Hep/NAC | N | 36 | Alive | 100 | 100 | 100 | 1 | 0 | Bacterial CVL infection | None | |||
6 | DF 25 | N | 31 | Alive | 100 | 90 | 85 | 0 | 0 | Rhinovirus, BCG | Mucositis (grade 2), PH (d+30), gut/renal salt protein losses, renal calcification (successful surgical removal) | |||
7 | DF 25 | Y | M | DF/steroids | Y | 24 | Alive | 100 | 98 | 88 | 0 | 0 | EBV, BCG | Hematemesis, rectal bleeding, diarrhea, early reactivation of HLH, renal impairment, arterial hypertension |
8 | Hep | Y | M | DF 40 | Y | 61 | Alive | 100 | 98 | 98 | 0 | 0 | N | Mucositis, GI problems, Hashimoto’s thyroiditis |
9 | NAC | Y | M | DF 40 paracentesis | Y | 15 | Alive | 100 | 9 | 42 | 0 | 0 | N | None |
10 | NAC | N | 51 | Alive | 100 | 100 | 100 | 0 | 0 | N | Mucositis (grade 1), CVL-associated atrial thrombus cured by surgical removal | |||
11 | Hep | Y | M | DF/steroids | Y | 88 | Alive | 100 | 90 | 89 | 0 | 0 | N | Mucositis (grade 2) |
12 | Hep | N | 111 | Alive | 100 | 94 | 92 | 1 | 0 | Urinary infection | Fever, mucositis (grade 2) | |||
13 | None | N | 45 | Alive | 100 | 100 | 100 | 1 | 0 | N | None | |||
14 | NAC | N | 63 | Alive | 40 | 100 | 98 | 0 | 0 | N | None | |||
15 | NAC | Y | S | DF/steroids, paracentesis, ventilation | Y | 43 | Alive | 100 | 95 | 96 | 0 | 0 | N | Mucositis (grade 2), ventilated, atelectasis left lung, urinary infection |
16 | NAC | Y | M | DF/steroids | Y | 31 | Alive | 100 | 100 | 99 | 1 | 0 | N | Recurrent CVL complications |
17 | NAC | N | 37 | Alive | 90 | 99,5 | 99,5 | 1 | 1 (oral/scalp) | Vulvitis with Pseudomonas | Mucositis (grade 2), engraftment syndrome, eosinophilic folliculitis of the scalp with partial effluvium, stomatitis, DD cGHVD | |||
18 | NAC | Y | M | DF/steroids/paracentesis | Y | 36 | Alive | 100 | 73 | 30 | 0 | 0 | N | Mucositis (grade 2) |
19 | NAC, DF 25 | N | 31 | Alive | 100 | 96 | 87 | 0 | 0 | N | None | |||
20 | NAC, DF 25 | N | 18 | Alive | 100 | 58 | 79 | 0 | 0 | Metapneumovirus, HHV-6 | None | |||
21 | Hep | N | 14 | Alive | 100 | 100 | 98,5 | 0 | 0 | Bacterial CVL infection | Mucositis grade 3 | |||
22 | None | Y | M | DF | Y | 22 | Alive | 100 | 100 | 81 | 0 | 0 | N | EBV viremia, rituximab |
23 | Hep/DF 25 | N | 8 | Alive | 100 | 67 | 74 | 0 | 0 | N | Mucositis (grade 3), seizure of unknown cause | |||
24 | NAC | N | 78 | Alive | 100 | 100 | 100 | 2 | 0 | N | Mucositis (grade 1), arterial hypertension | |||
25 | NAC | N | 49 | Alive | 100 | 97 | 97 | 2 | 0 | N | Engraftment syndrome, arthritis of 2 joints (intra-articular steroid injections) |
ADV, adenovirus; aGVHD, acute GVHD; BCG, bacillus Calmette-Guérin; cGVHD, chronic GVHD; CVL, central venous line; DC, donor chimerism; DD, differential diagnosis; DF, defibrotide; EBV, Epstein-Barr virus; FU, follow-up; GI, gastrointestinal; HEP, heparin; HHV-6, human herpesvirus 6; NAC, N-acetyl cysteine; NIH, National Institutes of Health; PH, pulmonary hypertension; SOS, sinusoidal obstruction syndrome.